Johnson & Johnson $JNJ Shares Purchased by America First Investment Advisors LLC

America First Investment Advisors LLC boosted its stake in shares of Johnson & Johnson (NYSE:JNJ) by 0.2% during the 2nd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The firm owned 150,762 shares of the company’s stock after buying an additional 254 shares during the quarter. Johnson & Johnson accounts for approximately 4.6% of America First Investment Advisors LLC’s portfolio, making the stock its 15th largest holding. America First Investment Advisors LLC’s holdings in Johnson & Johnson were worth $23,029,000 at the end of the most recent reporting period.

A number of other hedge funds and other institutional investors also recently modified their holdings of JNJ. GFG Capital LLC acquired a new position in Johnson & Johnson during the second quarter worth $35,000. Stone House Investment Management LLC purchased a new position in shares of Johnson & Johnson in the first quarter valued at $47,000. 1248 Management LLC acquired a new position in shares of Johnson & Johnson during the 1st quarter worth $48,000. Harvest Fund Management Co. Ltd purchased a new stake in shares of Johnson & Johnson in the 1st quarter worth about $52,000. Finally, Pandora Wealth Inc. purchased a new position in Johnson & Johnson during the 1st quarter valued at about $65,000. 69.55% of the stock is currently owned by institutional investors and hedge funds.

Johnson & Johnson Price Performance

Johnson & Johnson stock opened at $200.10 on Wednesday. The company has a debt-to-equity ratio of 0.50, a quick ratio of 0.80 and a current ratio of 1.07. The company has a market cap of $482.11 billion, a price-to-earnings ratio of 19.31, a PEG ratio of 2.19 and a beta of 0.38. Johnson & Johnson has a 1 year low of $140.68 and a 1 year high of $200.30. The firm has a 50 day moving average price of $186.69 and a 200 day moving average price of $170.77.

Johnson & Johnson (NYSE:JNJ) last announced its quarterly earnings results on Wednesday, August 30th. The company reported $2.26 earnings per share for the quarter. Johnson & Johnson had a net margin of 27.26% and a return on equity of 32.73%. The company had revenue of $24.02 billion for the quarter. Sell-side analysts predict that Johnson & Johnson will post 10.58 earnings per share for the current year.

Johnson & Johnson Dividend Announcement

The company also recently declared a quarterly dividend, which will be paid on Tuesday, December 9th. Shareholders of record on Tuesday, November 25th will be given a dividend of $1.30 per share. This represents a $5.20 dividend on an annualized basis and a yield of 2.6%. The ex-dividend date of this dividend is Tuesday, November 25th. Johnson & Johnson’s payout ratio is 50.19%.

Insider Buying and Selling

In other news, EVP Jennifer L. Taubert sold 56,471 shares of the firm’s stock in a transaction dated Thursday, September 4th. The stock was sold at an average price of $177.81, for a total value of $10,041,108.51. Following the transaction, the executive vice president directly owned 178,013 shares in the company, valued at $31,652,491.53. This trade represents a 24.08% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink. 0.16% of the stock is owned by corporate insiders.

Analyst Upgrades and Downgrades

Several analysts have issued reports on JNJ shares. Erste Group Bank raised shares of Johnson & Johnson from a “hold” rating to a “buy” rating in a report on Wednesday, July 23rd. HSBC upped their target price on Johnson & Johnson from $210.00 to $215.00 and gave the company a “buy” rating in a research note on Thursday, October 16th. JPMorgan Chase & Co. raised their price target on Johnson & Johnson from $185.00 to $200.00 and gave the stock a “neutral” rating in a research report on Tuesday, September 16th. Wells Fargo & Company set a $212.00 price objective on Johnson & Johnson and gave the company an “overweight” rating in a research report on Friday, October 3rd. Finally, Citigroup increased their price objective on Johnson & Johnson from $213.00 to $215.00 and gave the company a “buy” rating in a research note on Wednesday, October 15th. Four analysts have rated the stock with a Strong Buy rating, thirteen have given a Buy rating and nine have assigned a Hold rating to the company’s stock. According to data from MarketBeat, Johnson & Johnson currently has an average rating of “Moderate Buy” and a consensus target price of $201.05.

Johnson & Johnson Company Profile

Johnson & Johnson is a holding company, which engages in the research, development, manufacture, and sale of products in the healthcare field. It operates through the Innovative Medicine and MedTech segments. The Innovative Medicine segment focuses on immunology, infectious diseases, neuroscience, oncology, cardiovascular and metabolism, and pulmonary hypertension.